Literature DB >> 25049315

Prognostic significance and relationship of worst lead residual ST segment elevation with myocardial damage assessed by cardiovascular MRI in myocardial infarction.

K P Rommel1, A Baum1, M Mende2, S Desch3, M Gutberlet4, G Schuler1, H Thiele3, I Eitel3.   

Abstract

OBJECTIVE: To investigate the relation of residual worst lead ST segment elevation (WL-STE) after ST segment myocardial infarction (STEMI) with infarct size and microvascular injury assessed by cardiovascular magnetic resonance (CMR) imaging.
BACKGROUND: WL-STE in patients with acute reperfused STEMI has been shown to identify high risk patients for major adverse cardiovascular events (MACE). However, the relation of WL-STE with myocardial damage is unknown.
METHODS: In this multicentre study we analysed ECG data 90 min after primary percutaneous coronary intervention (PCI) in 763 STEMI patients. WL-STE was defined as the absolute magnitude of STE in the most affected lead on the post-PCI ECG. Patients were categorised into three groups (<1 mm, 1-2 mm, and ≥2 mm). CMR was performed within 1 week after infarction for comprehensive assessment of myocardial damage using a standardised protocol. The primary clinical endpoint was MACE defined as death, reinfarction, and new congestive heart failure within 12 months after infarction.
RESULTS: WL-STE <1 mm, 1-2 mm, and ≥2 mm was present in 155 (20%), 328 (43%), and 280 (37%) patients, respectively. Myocardial damage determined by CMR demonstrated a graded relationship of infarct size (median (IQR) 13.3 (6.2-20.3)%LV vs 13.7 (7.6-21.3)%LV vs 22.5 (15.6-31.2)%LV, p<0.001), the myocardial salvage index (60.8 (37.0-84.5) vs 55.0 (36.6-73.9) vs 42.7 (26.2-58.2), p<0.001), and microvascular obstruction (0.0 (0.0-0.9)%LV vs 0.0 (0-1.0)%LV vs 1.2 (0.0-3.6)%LV, p<0.001) across the three groups. WL-STE ≥2 mm was strongly associated with MACE 12 month after infarction (HR 1.93, 95% CI 1.11 to 3.37; p=0.02).
CONCLUSIONS: This largest CMR study to date correlating post-PCI WL-STE with markers of myocardial damage demonstrates that WL-STE is significantly associated with infarct size, myocardial salvage, microvascular obstruction, and MACE in a high risk STEMI population. TRIAL REGISTRATION NUMBER: NCT00712101. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Keywords:  cardiac magnetic resonance; electrocardiogram; infarction; prognosis

Mesh:

Substances:

Year:  2014        PMID: 25049315     DOI: 10.1136/heartjnl-2013-305462

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  3 in total

1.  Circulating Endothelial Cells and Endothelial Function Predict Major Adverse Cardiac Events and Early Adverse Left Ventricular Remodeling in Patients With ST-Segment Elevation Myocardial Infarction.

Authors:  Magdy Abdel Hamid; Sameh W G Bakhoum; Yasser Sharaf; Dina Sabry; Ahmed T El-Gengehe; Ahmed Abdel-Latif
Journal:  J Interv Cardiol       Date:  2016-02       Impact factor: 2.279

2.  QRS complex distortion (Grade 3 ischaemia) as a predictor of myocardial damage assessed by cardiac magnetic resonance imaging and clinical prognosis in patients with ST-elevation myocardial infarction.

Authors:  Karl-Philipp Rommel; Hadeel Badarnih; Steffen Desch; Matthias Gutberlet; Gerhard Schuler; Holger Thiele; Ingo Eitel
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2015-06-09       Impact factor: 6.875

3.  Worst lead ST deviation and resolution of ST elevation at one hour for prediction of myocardial salvage, infarct size, and microvascular obstruction in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention.

Authors:  Anne Line Stensjøen; Anders Hommerstad; Sigrun Halvorsen; Håkan Arheden; Henrik Engblom; David Erlinge; Alf-Inge Larsen; Maria Sejersten Ripa; Peter Clemmensen; Dan Atar; Trygve S Hall
Journal:  Ann Noninvasive Electrocardiol       Date:  2020-06-27       Impact factor: 1.468

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.